Finding new treatments for diabetes - How many, how fast ... How good?

被引：174

作者：

Nathan, David M. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2007年 / 356卷 / 05期

关键词：

PEPTIDASE-4 INHIBITOR SITAGLIPTIN; EFFICACY; SAFETY; MONOTHERAPY; THERAPY;

D O I：

10.1056/NEJMp068294

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：437 / 440

页数：4

共 5 条

[1] Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [J].

Aschner, Pablo ;

Kipnes, Mark S. ;

Lunceford, Jared K. ;

Sanchez, Matilde ;

Mickel, Carolyn ;

Williams-Herman, Debora E. .

DIABETES CARE, 2006, 29 (12) :2632-2637

[2]

*CDC PREV, 2004, NAT DIAB SURV SYST

[3] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J].

Charbonnel, Bernard ;

Karasik, Avraham ;

Liu, Ji ;

Wu, Mei ;

Meininger, Gary .

DIABETES CARE, 2006, 29 (12) :2638-2643

[4] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus [J].

Raz, I. ;

Hanefeld, M. ;

Xu, L. ;

Caria, C. ;

Williams-Herman, D. ;

Khatami, H. .

DIABETOLOGIA, 2006, 49 (11) :2564-2571

[5] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study [J].

Rosenstock, Julio ;

Brazg, Ronald ;

Andryuk, Paula J. ;

Lu, Kaifeng ;

Stein, Peter .

CLINICAL THERAPEUTICS, 2006, 28 (10) :1556-1568

← 1 →